Pure Global

A Study of IAP0971 in Combination With Bacillus Calmette Guerin in High Risk Non-muscular Invasive Bladder Cancer - Trial NCT06255964

Access comprehensive clinical trial information for NCT06255964 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by SUNHO（China）BioPharmaceutical CO., Ltd. and is currently Not yet recruiting. The study focuses on Bladder Cancer. Target enrollment is 236 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06255964
Phase 1/2
Not yet recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06255964
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
A Study of IAP0971 in Combination With Bacillus Calmette Guerin in High Risk Non-muscular Invasive Bladder Cancer
A Phase I/II Clincal Trial of Intravesical IAP0971 in Combination With Bacillus Calmette Guerin (BCG) in Patients With BCG Unresponsive High Risk Non-Muscular Invasive Bladder Cancer (NMIBC)

Study Focus

Bladder Cancer

IAP0971

Interventional

drug

Sponsor & Location

SUNHO（China）BioPharmaceutical CO., Ltd.

Timeline & Enrollment

Phase 1/2

Feb 15, 2024

Dec 07, 2026

236 participants

Primary Outcome

DLTs occurrence

Summary

The efficacy and safety of IAP0971 single drug or combined with BCG intravesical instillation
 in the treatment of high-risk non muscle invasive bladder cancer with BCG treatment failure.

ICD-10 Classifications

Malignant neoplasm of bladder
Malignant neoplasm: Bladder, unspecified
Malignant neoplasm: Dome of bladder
Malignant neoplasm: Overlapping lesion of bladder
Malignant neoplasm: Lateral wall of bladder

Data Source

ClinicalTrials.gov

NCT06255964

Non-Device Trial